Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials.
about
Antigen-based immunotherapy for autoimmune disease: current statusIslet inflammation: a unifying target for diabetes treatment?Type 1 diabetesInsulitis in human type 1 diabetes: a comparison between patients and animal modelsToward beta cell replacement for diabetesRebranding asymptomatic type 1 diabetes: the case for autoimmune beta cell disorder as a pathological and diagnostic entity.Combined therapy with GABA and proinsulin/alum acts synergistically to restore long-term normoglycemia by modulating T-cell autoimmunity and promoting β-cell replication in newly diabetic NOD mice.In search of a surrogate: engineering human beta cell lines for therapy.Characteristics and determinants of partial remission in children with type 1 diabetes using the insulin-dose-adjusted A1C definitionRestoration of the unfolded protein response in pancreatic β cells protects mice against type 1 diabetes.β-Cell-targeted blockage of PD1 and CTLA4 pathways prevents development of autoimmune diabetes and acute allogeneic islets rejection.Expression profiling pre-diabetic mice to uncover drugs with clinical application to type 1 diabetes.Combination Therapy Reverses Hyperglycemia in NOD Mice With Established Type 1 Diabetes.Immunotherapy trials for type 1 diabetes: the contribution of George Eisenbarth.Comparative genetics: synergizing human and NOD mouse studies for identifying genetic causation of type 1 diabetesPerinatal tolerance to proinsulin is sufficient to prevent autoimmune diabetes.Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes.Introduction to personalized medicine in diabetes mellitus.Plant-based vaccines for oral delivery of type 1 diabetes-related autoantigens: Evaluating oral tolerance mechanisms and disease prevention in NOD mice.It's time to bring dendritic cell therapy to type 1 diabetes.Type 1 diabetes therapy beyond T cell targeting: monocytes, B cells, and innate lymphocytesCD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.Concise review: pluripotent stem cell-based regenerative applications for failing β-cell functionDeveloping a vaccine for Type 1 diabetes through targeting enteroviral infections.Impact of disease heterogeneity on treatment efficacy of immunotherapy in Type 1 diabetes: different shades of gray.JDRF's vision and strategy for prevention of type 1 diabetes.Depletion of IL-2 receptor β-positive cells protects from diabetes in non-obese diabetic mice.Status of autoimmune diabetes 20-year after generation of BDC2.5-TCR transgenic non-obese diabetic mouse.Generation of β cell-specific human cytotoxic T cells by lentiviral transduction and their survival in immunodeficient human leucocyte antigen-transgenic mice.Antibody Binding to CD4 Induces Rac GTPase Activation and Alters T Cell Migration.Therapeutic targeting of B cells and T cells in autoimmune diabetes: is it a solution?Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes.Optimizing Multiplexed Detections of Diabetes Antibodies via Quantitative Microfluidic Droplet Array.Loss of intra-islet heparan sulfate is a highly sensitive marker of type 1 diabetes progression in humans.[Insulitis in type 1 diabetes].Human mesenchymal stem cell-derived microvesicles modulate T cell response to islet antigen glutamic acid decarboxylase in patients with type 1 diabetes
P2860
Q26852915-0B4DC990-4CDA-4432-98DE-C7FC7FE06063Q26860847-F27D63A9-3D86-4E22-AA3E-AC435025C107Q27000491-886B69FB-F36C-4620-838C-3D685E917F88Q27023712-FC3C05B1-62FF-41E5-9D3E-5F75E56A867AQ28083650-728917BD-00B6-4005-9B69-728BB0EA0FEAQ33916508-9F52B078-8FC2-47B5-9840-30B0AC1B9980Q34077377-6E45E1C5-7D4C-42CC-AB85-8167F9CD0C1CQ34117681-66539514-D8EA-4FC7-8623-B12BCE0D3F0DQ34181376-7CDD05B4-5D75-4CFF-AFEB-E1A32E15493AQ34213205-EFDA2B78-44B6-43A4-949E-B48BF4755D00Q35904021-4962C0F9-A350-4AD2-93A8-24A50BEDBE3BQ36022067-CB658DEC-316F-4CB1-AD98-9A27F96293E1Q36186226-258A8AA1-5A16-4FDB-A7D2-EED6BC1112D0Q36913132-E928B800-CA3C-4ED4-8983-F3509D53DB37Q37088185-D6C0EDEE-1B35-4464-82A0-D5B140FF16B2Q37277296-75AB6397-18C1-4343-9436-7A2F5FE2FF83Q37478584-062F12CB-286B-44AC-9FB4-0C04043A1E1EQ37523745-02DA3B14-DAD6-46D7-9C46-A50E919562DFQ37638227-37F8A8FE-5377-4DB8-876A-0599C1788833Q37670174-B491AF83-68AD-4306-BDBF-2EFFEAF1E505Q38117282-3C488B29-4084-4975-B692-534AFB365B27Q38117284-A5D721B7-2927-4FFA-8B1F-BCF86B19C72CQ38197390-64492673-2D58-43B7-8178-6672DD616FD1Q38223233-919B7524-149B-43A8-B68B-E4E6DD760885Q38365047-763E96B2-C017-4EAF-A481-C37B515189AFQ38895435-DFCFBA76-DCE4-480B-BF2A-FE67975F4E50Q41070908-93F0D280-5BA2-407C-BAB0-0133BAA592C5Q41782901-C414083A-7114-46BF-A778-45B0806018FFQ42183951-9C764B0F-D8E5-4510-8372-22EE252519F2Q42737518-1A09881E-E150-41EC-BF55-9B37465B5B7BQ42869996-668D38BA-5629-4F85-8846-A421EF1D244FQ45929111-E6E68167-2FBB-4703-B8DE-2A353164F7AAQ47153962-FF60B2F2-0160-4B96-BB2E-82F609EBB09DQ50133247-90BE66D8-D251-4743-9D48-81EA7B9F57BFQ53112191-E38900A4-61D4-4C56-BC2A-D910C9C3821CQ58831436-30F51243-910B-46D3-9240-3EF1DD9708A6
P2860
Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Recent lessons learned from pr ...... diabetes immunotherapy trials.
@ast
Recent lessons learned from pr ...... diabetes immunotherapy trials.
@en
Recent lessons learned from pr ...... diabetes immunotherapy trials.
@nl
type
label
Recent lessons learned from pr ...... diabetes immunotherapy trials.
@ast
Recent lessons learned from pr ...... diabetes immunotherapy trials.
@en
Recent lessons learned from pr ...... diabetes immunotherapy trials.
@nl
prefLabel
Recent lessons learned from pr ...... diabetes immunotherapy trials.
@ast
Recent lessons learned from pr ...... diabetes immunotherapy trials.
@en
Recent lessons learned from pr ...... diabetes immunotherapy trials.
@nl
P2093
P2860
P356
P1433
P1476
Recent lessons learned from pr ...... diabetes immunotherapy trials.
@en
P2093
Mark A Atkinson
Richard Insel
Teodora P Staeva
P2860
P356
10.2337/DB12-0562
P407
P5008
P577
2013-01-01T00:00:00Z